Cargando…

Incorporating Truncating Variants in PALB2, CHEK2 and ATM into the BOADICEA Breast Cancer Risk Model

PURPOSE: The proliferation of gene-panel testing precipitates the need for a breast cancer (BC) risk model that incorporates the effects of mutations in several genes and family history (FH). We extended the BOADICEA model to incorporate the effects of truncating variants in PALB2, CHEK2 and ATM. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Andrew J., Cunningham, Alex P., Tischkowitz, Marc, Simard, Jacques, Pharoah, Paul D., Easton, Douglas F., Antoniou, Antonis C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086091/ https://www.ncbi.nlm.nih.gov/pubmed/27464310 http://dx.doi.org/10.1038/gim.2016.31

Ejemplares similares

Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks
por: Decker, Brennan, et al.
Publicado: (2017)

BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors
por: Lee, Andrew, et al.
Publicado: (2019)

Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors
por: Lee, Andrew, et al.
Publicado: (2019)

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
por: Southey, Melissa C, et al.
Publicado: (2016)

Clinical software development for the Web: lessons learned from the BOADICEA project
por: Cunningham, Alex P, et al.
Publicado: (2012)

Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
por: Mavaddat, Nasim, et al.
Publicado: (2023)

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families
por: Antoniou, Antonis C, et al.
Publicado: (2006)

The BOADICEA model of genetic susceptibility to breast and ovarian cancer
por: Antoniou, A C, et al.
Publicado: (2004)

Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence
por: Lee, Andrew, et al.
Publicado: (2022)

Reply: Remarks on the BOADICEA model of genetic susceptibility to breast and ovarian Cancer Research UK
por: Antoniou, A C, et al.
Publicado: (2005)

Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries
por: Brédart, Anne, et al.
Publicado: (2017)

Characterisation of protein-truncating and missense variants in PALB2 in 15 768 women from Malaysia and Singapore
por: Ng, Pei Sze, et al.
Publicado: (2022)

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk
por: Baynes, Caroline, et al.
Publicado: (2007)

Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?
por: Byrnes, Graham B, et al.
Publicado: (2008)

Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study
por: Yang, Xin, et al.
Publicado: (2022)

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface
por: Lee, A J, et al.
Publicado: (2014)

Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer
por: Woodward, Emma R., et al.
Publicado: (2021)

Association of genetic variants in ATR-CHEK1 and ATM-CHEK2 pathway genes with risk of colorectal cancer in a Chinese population
por: Wang, Shijia, et al.
Publicado: (2018)

Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer
por: Grant, Robert C, et al.
Publicado: (2013)

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions
por: Antoniou, A C, et al.
Publicado: (2008)

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions
por: Antoniou, A C, et al.
Publicado: (2008)

Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses
por: Ng, Pei Sze, et al.
Publicado: (2021)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model
por: Gallagher, Shannon, et al.
Publicado: (2021)

Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations
por: Vysotskaia, Valentina, et al.
Publicado: (2019)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women
por: Foulkes, William D, et al.
Publicado: (2007)

Functional characterization of 84 PALB2 variants of uncertain significance
por: Wiltshire, Timothy, et al.
Publicado: (2019)

Familial wild-type gastrointestinal stromal tumour in association with germline truncating variants in both SDHA and PALB2
por: Whitworth, James, et al.
Publicado: (2021)

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years
por: Petridis, Christos, et al.
Publicado: (2019)

Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry
por: Pal Choudhury, Parichoy, et al.
Publicado: (2021)

A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects
por: Jervis, Sarah, et al.
Publicado: (2015)

Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort
por: Lakeman, Inge M. M., et al.
Publicado: (2020)

BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis
por: Nyberg, Tommy, et al.
Publicado: (2021)

Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2
por: Boonen, Rick A. C. M., et al.
Publicado: (2019)

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
por: Bychkovsky, Brittany L., et al.
Publicado: (2022)

A PALB2 mutation associated with high risk of breast cancer
por: Southey, Melissa C, et al.
Publicado: (2010)

Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors
por: Lee, Andrew, et al.
Publicado: (2022)

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
por: Francies, F. Z., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9nv5mdnc08otlhb69t09flvqgp